Artiva Biotherapeutics CEO reports selling 3,187 shares at $6

Artiva Biotherapeutics, Inc. reported an insider stock sale by its president and CEO, who also serves as a director.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. reported an insider stock sale by its president and CEO, who also serves as a director. On December 15, 2025, the insider sold 3,187 shares of common stock at $6 per share.

Following this transaction, the insider directly owned 1,209,948 shares of Artiva Biotherapeutics common stock. The filing notes that the sale occurred under a Rule 10b5-1 trading plan adopted by the reporting person on July 23, 2024.

Insider Trade Summary

Net Seller: 3,187 shares

Net Sell 1 txn

Insider Aslan Fred

Role President and CEO

Sold 3,187 shs ($19K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,187	$6.00	$19K

Holdings After Transaction: Common Stock — 1,209,948 shares (Direct)

Footnotes (1)

1. F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on July 23, 2024.

FAQ

What insider transaction did Artiva Biotherapeutics (ARTV) disclose?

Artiva Biotherapeutics disclosed that its president and CEO, who is also a director, sold 3,187 shares of common stock in a reported transaction.

At what price were the ARTV shares sold in this insider transaction?

The reported sale involved 3,187 shares of Artiva Biotherapeutics common stock at a price of $6 per share.

How many Artiva Biotherapeutics (ARTV) shares does the insider hold after this sale?

After the transaction, the insider directly beneficially owned 1,209,948 shares of Artiva Biotherapeutics common stock.

When did the reported Artiva Biotherapeutics (ARTV) transaction occur?

The insider transaction took place on December 15, 2025, as reported in the filing.

Was the ARTV insider trade made under a Rule 10b5-1 trading plan?

Yes. The filing explains that the reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on July 23, 2024.

What is the reporting form type for this Artiva Biotherapeutics (ARTV) insider transaction?

The insider transaction was reported on a Form 4, which discloses changes in beneficial ownership by company insiders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/15/2025 - 09:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aslan Fred

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		S		3,187(1)	D	$6	1,209,948	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on July 23, 2024.

	/s/ Andrew Cronauer, Attorney-in-Fact	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.